Market Access News | pharmaphorum

News

RFK Jr expands ACIP ahead of highly anticipated meeting

Five members have been added to a controversial CDC vaccines panel ahead of a meeting this week that could have an impact on US immunisation policy.

News

Novo's oral GLP-1 is first to claim heart health label

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction.

News

AbbVie loses bid to block 340B law in Mississippi

Battle lines are being drawn on 340B rebates as AbbVie loses a bid to block a Mississippi law seeking to retain discounts for contract pharmacies.

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News

Intercept pulls Ocaliva off the market in the US

Alfasigma's $800m buyout of Intercept is starting to look like a poor bet as its only product, Ocaliva, is pulled from the market.

RFK Jr expands ACIP ahead of highly anticipated meeting

Novo's oral GLP-1 is first to claim heart health label

AbbVie loses bid to block 340B law in Mississippi

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Intercept pulls Ocaliva off the market in the US

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks